Evidence map›Paper›PMID 24955019›Full record

ArticleCurrent opinion in colloid & interface science2014

Inorganic Nanoparticles for Therapeutic Delivery: Trials, Tribulations and Promise.

Gulen Yesilbag Tonga, Daniel F Moyano, Chang Soo Kim, Vincent M Rotello

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current opinion in colloid & interface science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. NaCl Nanoparticles as a Cancer Therapeutic.Advanced materials (Deerfield Beach, Fla.) · 2019
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gulen Yesilbag TongaDepartment of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA, 01003, USA.
Daniel F MoyanoDepartment of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA, 01003, USA.
Chang Soo KimDepartment of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA, 01003, USA.
Vincent M RotelloDepartment of Chemistry, University of Massachusetts Amherst, 710 North Pleasant Street, Amherst, MA, 01003, USA.

Funding

Recognition and Presentation of Alpha Helices using Nanoparticle ReceptorsR01GM077173 · NIGMS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ROTELLO, VINCENT M. · 2007 to 2018
$3.7M
Intracellular Host-Guest Activation of Nanoparticle TherapeuticsR01EB014277 · NIBIB · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ROTELLO, VINCENT M. · 2012 to 2014
$1.0M
NIBIB NIH HHS R01 EB014277NIGMS NIH HHS R01 GM077173
6 · The paper itself

Abstract

Inorganic nanomaterials have a wide array of physical and structural properties that make them attractive candidates for imaging and therapeutic delivery. Nanoparticle platforms have been intensely studied for these applications, and examples are starting to enter the clinic. This review looks at why inorganic particles provide promising platforms for biomedicine, and what issues need to be addressed for them to reach their potential.

Indexed as

bio-nano interfacedrug deliveryimaging agentinorganic nanomaterialstheranosticup converting nanoparticles

Identifiers

PMID24955019
PMCPMC4061753

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.